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Enzyme-dependent fluorescence
recovery of NADH after
photobleaching to assess
dehydrogenase activity of isolated
perfused hearts
Angel Moreno, Sarah Kuzmiak-Glancy, Rafael Jaimes 3rd & Matthew W. Kay
Reduction of NAD+ by dehydrogenase enzymes to form NADH is a key component of cellular
metabolism. In cellular preparations and isolated mitochondria suspensions, enzyme-dependent
fluorescence recovery after photobleaching (ED-FRAP) of NADH has been shown to be an effective
approach for measuring the rate of NADH production to assess dehydrogenase enzyme activity. Our
objective was to demonstrate how dehydrogenase activity could be assessed within the myocardium
of perfused hearts using NADH ED-FRAP. This was accomplished using a combination of high intensity
UV pulses to photobleach epicardial NADH. Replenishment of epicardial NADH fluorescence was then
imaged using low intensity UV illumination. NADH ED-FRAP parameters were optimized to deliver
23.8 mJ of photobleaching light energy at a pulse width of 6 msec and a duty cycle of 50%. These
parameters provided repeatable measurements of NADH production rate during multiple metabolic
perturbations, including changes in perfusate temperature, electromechanical uncoupling, and acute
ischemia/reperfusion injury. NADH production rate was significantly higher in every perturbation where
the energy demand was either higher or uncompromised. We also found that NADH production rate
remained significantly impaired after 10 min of reperfusion after global ischemia. Overall, our results
indicate that myocardial NADH ED-FRAP is a useful optical non-destructive approach for assessing
dehydrogenase activity.
Fluorescence recovery after photobleaching (FRAP) is a popular approach for studying the temporal dynamics
and diffusion kinetics of fluorescent and fluorescently labeled molecules within living cells1. Enzyme-dependent
FRAP (ED-FRAP) is useful for measuring enzyme kinetics and involves the photolysis of a product of an enzyme
reaction and the subsequent analysis of the replenishment of that product2–4. ED-FRAP is particularly useful for
studying the rate of production of NADH, an important reducing agent and endogenous fluorophore (excitation
360 nm, emission 460 nm). NAD+ is reduced by cellular dehydrogenase enzymes to generate NADH and the
NAD+: NADH redox couple is a highly regulated component of cellular metabolism5–7. NADH drives ATP production in the mitochondria and the NAD+: NADH ratio reflects the balance between the reduction of NAD+ via
substrate oxidation and the oxidation of NADH for oxidative phosphorylation8.
In cardiomyocytes, the NAD+: NADH ratio is dependent upon multiple factors9, including available substrate8,10–12, cardiac work5,13, and myocardial oxygenation13,14. NAD+: NADH ratios reported in the literature
for normoxic perfused hearts range from 22% reduced15 to as high as 80% reduced10. Cellular NAD+ and
NADH concentrations can be measured using absorbance assays but this typically requires cellular manipulation that destroys cells16, eliminating the ability to measure concentration changes over time from living cells.
A non-destructive alternative is to measure NADH fluorescence (fNADH) from living cells and tissue, which
provides a quantitative assessment of the NAD+: NADH ratio that is consistent with that provided by biochemical
assays of NAD+ and NADH concentrations17.
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NADH fluorescence is typically monitored from cardiac tissue by illuminating tissue with low intensity ultraviolet (UV) light and acquiring the resulting fluorescence between 450–475 nm5,8,11,13,14,18. Our recent studies
in perfused hearts demonstrate how epicardial fNADH fluctuations reveal changes in NADH production and
consumption (oxidation) during physiologic perturbations11,13. An important limitation is that such fluctuations
are the combination of NADH production and NADH consumption, so neither the rate of NADH production,
nor the rate of consumption, can be independently measured using fluorescence alone. For example, an increase
in fNADH could indicate either an increase in the rate of NADH production, a decrease in the rate of NADH consumption, or be an indication of an oxygen limitation, resulting in progressive NADH production with negligible
consumption until reaching the fully reduced state.
Using cellular preparations and isolated mitochondria suspensions, Combs and Balaban measured the rate
of fNADH recovery after NADH photolysis to introduce NADH ED-FRAP as an assessment of dehydrogenase
activity2,3. They showed that the rate of fNADH recovery, measured within the setting of steady-state NADH consumption, was proportional to the activity (concentration) of glutamate dehydrogenase (GDH), a mitochondrial
enzyme that produces NADH during amino acid catabolism. The advantages of NADH ED-FRAP are that NAD+
is produced by the photolysis of NADH without destroying NADH molecules3; the kinetic properties of the
tricarboxylic acid (TCA) cycle are not altered2; and most of the fNADH signal is confined to the mitochondria19
because NADH does not diffuse from adjacent regions, in contrast to standard FRAP techniques20,21. As a result,
fNADH recovery during NADH ED-FRAP is dominated by the production of NADH by the dehydrogenase
enzymes of the TCA cycle. With these advantages, NADH ED-FRAP provides additional insight into myocardial
energetics, above that of monitoring unbleached fNADH, by providing a direct assessment of the rate of mitochondrial NADH production.
However, to date, no studies have demonstrated how the rate of NADH production could be assessed in
perfused hearts using NADH ED-FRAP22. This would be an important advancement because perfused hearts
are a popular experimental approach for studying electromechanical function, metabolism, and arrhythmias,
primarily because precise control of experimental variables such as fuel supply, pressure, and temperature can
be maintained11,13,23,24. Therefore, the goal of the present study was to expand the technique of NADH ED-FRAP
to perfused hearts and use it to study the rate of NADH production during controlled metabolic perturbations.
We demonstrate for the first time that NADH ED-FRAP is a useful approach for measuring the rate of
NADH production in contracting perfused hearts. The approach was implemented using high-power UV
light-emitting diodes (LEDs) and a high-speed CCD camera. The optimal energy delivery of 23.8 mJ of UV light
(367.5 ± 5.5 nm) was found by modulating the light intensity and pulse width while measuring the NADH photobleaching fraction and ensuring adequate recovery of fluorescence under controlled conditions. We also tested
the efficacy of NADH ED-FRAP for measuring changes in NADH production rate in hearts perfused at low
temperatures, in the presence and absence of mechanical contraction, and before and after ischemia/reperfusion
injury. These new results provide insight into how NADH production rate is adjusted to couple with the energy
demand of specific physiologic conditions.

Results

Our NADH ED-FRAP approach for measuring dehydrogenase activity in isolated perfused hearts is presented
in Fig. 1. High power UV light was focused on the LV epicardium to photobleach NADH within an area of
~7 mm2 (Fig. 1A). The LV epicardium was then illuminated with low power UV light to image fNADH (Fig. 1B).
Recovery kinetics of fNADH were measured from the images within a region of interest selected to contain the
photobleached tissue (Fig. 1C,D).

Estimated percentage of NADH pool photobleached.

Studies were conducted (n = 8) to measure
the percentage of the total NADH pool ([NAD+] + [NADH]) that was photobleached during a typical NADH
ED-FRAP measurement. This was done by imaging epicardial NADH fluorescence after full NADH oxidation
(via administering CCCP) and after full NADH reduction (during global ischemia) to assess the full range of
fNADH. During control conditions, average baseline fNADH before photobleaching indicated that the NAD+:
NADH redox poise of epicardial tissue in our studies was 50.7 ± 4.5% reduced and 49.3 ± 4.5% oxidized (Fig. 1B).
These values are consistent with previous studies in isolated hearts where levels of fNADH indicated the redox
poise to be within the range of 50% reduction when glucose was the only exogeneous substrate10. This is also consistent with whole-cell NAD+: NADH ratios measured using an absorbance assay kit for myocytes isolated from
healthy mouse hearts16. The ratio was approximately one, indicating a redox poise for isolated cardiomyocytes
to be 50% reduced and 50% oxidized. In our studies, we found that the application of 23.8 mJ of photobleaching
energy lowered baseline fNADH by 13.2 ± 2.3%, thereby increasing the redox poise of the photobleached tissue
to 62.5 ± 3.8% oxidized (Fig. 1B).

Total energy delivered (TED) during NADH ED-FRAP.

We found that a minimum TED must be
administered to the epicardial surface to achieve repeatable NADH photobleaching. Increasing TED from 2.8 to
18.2 mJ increased percent photobleaching for each photobleaching mode (Long Pulse - LP, Short Pulse - SP, Low
Light Power - LLP and Single Pulse - 1P) (p < 0.001) (Fig. 2A). As TED was increased from 18.2 to 28 mJ, there
was little increase in percent photobleaching. For all modes, percent photobleaching for TED greater than 18.2 mJ
was compared to percent photobleaching at a TED of 23.8 mJ and the differences were not significant (p >  0.05),
indicating that maximal photobleaching could be assured with a TED of 23.8 mJ. The exception was when TED
was delivered with the 1P mode: an increase in TED above 18.2mJ increased percent photobleaching beyond that
of the SP and LP modes (p < 0.05) (Fig. 2A). However, for the 1P mode, percent photobleaching for TED equal to
or greater than 18.2 mJ was not significantly greater than that of 23.8 mJ.
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Figure 1. (A) Photobleaching UV light was focused on the LV epicardium within an area of ~7 mm2 (orange
circle) and delivered as one of four modes (Table 1). (B) A typical NADH ED-FRAP signal is plotted within
the range of the estimated total NADH pool. The application of 23.8 mJ of photobleaching energy typically
lowered baseline fNADH by 13.2 ±  2.3%. Inset: Normalized fNADH signals are shown for one heart during
full reduction (global ischemia at t = 50 sec) and for another heart during full oxidation (CCCP administered at
t = 50 sec). The non-normalized signals were used to estimate the total NADH pool. (C) An example of spatial
fNADH recovery profiles from 0 to 40 sec after photobleaching the area shown in the fNADH image (yellow
dotted line). Within 40 sec the spatial fNADH profile returned to baseline levels and was indistinguishable from
the fNADH of surrounding unbleached tissue. (D) Measurements extracted from NADH ED-FRAP signals:
(1) Percent photobleaching was measured from baseline (fNADH at t < 5 sec) to the maximum fNADH drop
(fNADH at t = 5 sec); (2) Percent recovery was measured from baseline to the steady-state fNADH recovery
value; (3) Recovery time constant tau was measured as the time to 63% of full fNADH recovery; (4) The initial
slope of recovery was measured as the straight-line slope of change in fNADH during the first second of
recovery.

The initial slope of recovery was also dependent upon the TED. Initial slope increased as TED was increased
from 2.8 to 14 mJ across all photobleaching modes, with initial slope remaining constant as TED was increased
from 18.2 to 28 mJ (Fig. 2B). Unlike percent photobleaching and initial slope, the percent recovery of fNADH was
very consistent for all TEDs (Fig. 2C). When grouping all photobleaching modes together, percent recovery was
98.4 ± 0.45% at the lowest TED, and only decreased slightly to 97.2 ± 0.31% at the highest TED.
Significant variability was observed across photobleaching modes in measurements of the recovery time constant tau (Fig. 2D). For all modes at a TED greater than 7 mJ, tau was consistently shorter when the TED was
delivered with the LP or SP modes compared to LLP and 1 P modes (Fig. 2D) (p < 0.001). Tau for LLP and 1P
modes was significantly longer than that of LP (p < 0.001), meaning fNADH recovery was slower for these photobleaching modes. These differences occurred despite equal initial slopes of recovery for all photobleaching
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Figure 2. The effect of photobleaching mode (Table 1) and total energy delivered (TED) on NADH EDFRAP measurements during control conditions in perfused hearts (n = 5 for each mode at each TED). (A)
Percent photobleaching is plotted for each TED between 2.8 and 28 mJ for the four photobleaching modes.
For each mode, photobleaching increased until 18.2 mJ, where it reached a maximum. Astericks indicate
significant differences within each mode for comparisons between each TED and a TED of 23.8 mJ. (B) Initial
slope of fNADH recovery plotted for TED between 2.8 and 28 mJ for the four photobleaching modes. Initial
slope increased within each mode until 18.2 mJ, where it reached a maximum. Astericks indicate significant
differences within each mode for comparisons between each TED and a TED of 23.8 mJ. (C) Percent recovery
plotted for TED between 2.8 and 28 mJ for the four photobleaching modes. For all modes, percent recovery
approached 100% and was not dependent upon TED (p >  0.05). (D) Recovery time constant tau plotted for
TED between 2.8 and 28 mJ for the four photobleaching modes. Tau varied with photobleaching mode for
a particular TED but the effect of TED on tau within each photobleaching mode did not reach statistical
significance (p > 0.05). Crosses indicate significant differences for each TED for tau measured using LLP, SP, and
1 P photobleaching modes compared to tau measured using the LP mode.

modes at the same TED (Fig. 2B). Comparing tau within individual photobleaching modes across all TEDs did
not indicate that TED had a significant effect on tau.

NADH ED-FRAP and tissue viability.

Studies were conducted to verify that the low power UV illumination (1.5 mW) used to image epicardial fNADH would not cause tissue photodamage or significant NADH
photobleaching. First, fNADH was continuously acquired from an epicardial region of interest while illuminating
the epicardium for 35 sec, then the low power UV light was turned off for 40 sec and back on for another 35 sec.
fNADH was acquired again from the same region of interest during 100 sec of constant illumination, which is
the time typically required for one NADH ED-FRAP measurement. fNADH signals from a study are shown in
Fig. 3A, which indicate that NADH fluorescence is not lower when the low power UV light was on compared to
what it would be if the light were off (circled region in Fig. 3A). Similar studies were completed by Combs and
Balaban in isolated myocytes and demonstrated a slow constant decline of fNADH during steady-state UV illumination, mainly due to the balance between the net product of NADH photolysis and its metabolic production2. In
contrast, our measurements in perfused hearts indicate stable fNADH during steady-state illumination without
detectable photobleaching caused by low power UV illumination.
Epicardial tissue remained viable after several rounds of photobleaching, even after the maximal TED of
28 mJ was applied. Percent photobleaching, tau, initial slope of recovery, and percent recovery in a photobleached
region were not altered by previous NADH ED-FRAP applications. This is shown for percent photobleaching
in Fig. 3B, where TED for a single site was increased from 2.8 to 28 mJ then decreased from 28 to 2.8 mJ. This
“round-trip” NADH ED-FRAP shows that photobleaching percentage is dependent upon the amount of energy
imparted to the heart but not the order in which it is applied. However, we did observe that repeated application
of high power UV light to the same area caused irreversible NADH photolysis. This is evident after 6–8 rounds
of ED-FRAP at high energies (18.2–28 mJ), as shown in Fig. 3C. Four applications of such high energy caused a
sustained fNADH loss of up to 10% with respect to the first application. Even so, triphenyltetrazolium chloride
(TTC) staining indicated that the tissue remained viable (Fig. 3D). Altogether, these results indicate that NADH
Scientific Reports | 7:45744 | DOI: 10.1038/srep45744
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Figure 3. Sustained NADH photolysis and tissue viability after NADH ED-FRAP. (A) Normalized fNADH
is plotted to illustrate that low power UV illumination (1.5 mW) used to image fNADH does not cause
measurable NADH photobleaching in excised hearts. A sequence of light on-off-on shows that fNADH after
continuous illumination matches that of fNADH immediately after a 40 sec interval of darkness (circled). (B)
Percent photobleaching is not altered by previous applications of photobleaching light (LP mode). Results are
shown for a “round trip” experiment where TED was increased from 2.8 to 28 mJ then decreased from 28 to
2.3 mJ for the same region of tissue (n = 3 hearts). (C) Sustained NADH photolysis was observed (indicated by a
sustained drop in fNADH) after applying six rounds of high energy (18.2–28 mJ, LP mode) to the same areas of
tissue (circled). (D) Less than six applications of high energy (18.2–28 mJ, LP mode) to the same region of tissue
did not affect tissue viability, as evidenced in the image shown by the absence of pale epicardial tissue within
photobleached regions after TTC staining.

ED-FRAP at TED between 18.2–28 mJ should be limited to no more than three or four applications per site to
avoid sustained NADH photolysis.
Epicardial tissue exposed to the LP photobleaching mode did not exhibit evidence of cellular damage in either
TTC staining assessments (Figs 3D and 4B) or haematoxylin and eosin (H&E) cellular histology assessments
(Fig. 4E). NADH ED-FRAP was repeated three times at same epicardial site to further confirm that the LP photobleaching mode did not detrimentally impact tissue viability and measurement repeatability. Tau and initial
slope of recovery were compared after each application (Fig. 4C). No significant difference (p > 0.05) was detected
when measurements from the second and third application were compared to the first application. This suggests
that tissue viability was not detrimentally altered after three or less applications of NADH ED-FRAP. As a positive control, other hearts were subjected to 10 min of continuous UV illumination at the maximum LED power
(500 mW). TTC and H&E assessments were repeated. As expected, TTC staining revealed metabolically inactive
tissue within the areas that were subjected to the 10 min of 500 mW UV illumination (Fig. 4A,B). However, histological analysis did not reveal cellular morphology changes and many nuclei maintained a highly defined and
normal shape (Fig. 4F).
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Figure 4. Assessment of UV illumination effects on tissue viability and cell morphology. (A) After TTC
staining of positive controls, non-viable epicardial tissue was revealed at sites exposed to 10 min of continuous
UV illumination at max power (500 mW). (B) Cross-section of a heart after TTC staining reveals the
transmurality of non-viable tissue in positive controls exposed to high intensity UV illumination for 10 min
(500 mW). The high intensity illumination damaged the tissue up to a depth of approximately 0.5 mm. Adjacent
tissue exposed to the optimized NADH ED-FRAP protocol (LP mode) remained viable with no visible evidence
of epicardial or transmural damage. (C) No difference in measurements of NADH production rate were
detected (p > 0.05) after three applications of NADH ED-FRAP to the same epicardial site. Five minutes elapsed
between each measurement. Tau (top) and initial slope of recovery (bottom) were the same after the second and
third NADH ED-FRAP measurement compared to the first measurement. Error bars in this panel correspond
to standard deviation. (D) H&E staining of an LV short axis section within the area that was not illuminated.
As expected, no changes in cellular morphology were observed. (E) H&E staining of an LV short axis section
within the area that was exposed to three applications of NADH ED-FRAP using the LP photobleaching mode.
No changes in cellular morphology were observed. (F) H&E staining of an LV short axis section within the area
that was exposed to high intensity UV illumination for 10 min (500 mW). No changes in cellular morphology
were observed even though TTC staining revealed that this tissue was not viable, as shown in Panel B.

Dehydrogenase activity and temperature. Hearts were perfused at three temperatures to evaluate the
effect of temperature on NADH production rate. The rate of fNADH recovery after photobleaching increased
as temperature increased from 22 to 37 °C (Fig. 5A,B). Although percent photobleaching was not different at
30 & 37 °C, photobleaching was greater at 22 °C compared to higher temperatures (Fig. 5C) (p <  0.001). This
is likely the result of slowed NADH production at lower temperature. Photobleaching during slow NADH
production would achieve a higher level of NADH photolysis, thereby increasing percent photobleaching. Of
note is that fNADH only recovered to 95.12 ± 0.45% at 22 °C compared to 97.11 ± 0.34% and 96.58 ±  0.42% at
30 & 37 °C, respectively, likely due to slow NADH production at low temperatures. Glutamate dehydrogenase
(GDH) activity was measured in enriched mitochondrial fractions at the same three temperatures to validate the
NADH ED-FRAP results. GDH activity significantly increased from 4.50 ± 0.28nmol/mg-protein/min at 22 °C to
6.03 ± 0.35 and 7.56 ± 0.45 nmol/mg-protein/min at 30 & 37 °C (p < 0.001), respectively. These values were highly
correlated with values of fNADH initial slope and tau measured via NADH ED-FRAP (Fig. 5D).
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Figure 5. NADH ED-FRAP measurements (LP mode) for hearts perfused at three temperatures.
Hearts were electromechanically uncoupled with BDM. (A) The initial slope of fNADH recovery increases
with temperature (p <  0.001, n =  5). (B) The time constant of fNADH recovery (tau) drops with increasing
temperature (p <  0.001, n =  5) (C) Percent photobleaching is greater at 22 °C (p <  0.001, n = 5) but not
significantly different at 30 & 37 °C. (D) Initial slope and tau measured from hearts perfused at 22, 30, and 37 °C
are plotted with GDH activity (n = 4) measured at the same temperatures. (E) Representative fNADH data
acquired during NADH ED-FRAP were fitted (‘y’ in Equation 4) and plotted for the three temperatures studied.

Dehydrogenase activity and contraction. The effect of actomyosin ATPase inhibition was studied using
NADH ED-FRAP to determine if the rate of NADH production would correspond to a reduction in myocardial
energy consumption resulting from diminished actomyosin ATPase activity. Typical fNADH recovery curves for
contracting and non-contracting hearts after actomyosin ATPase inhibition with BDM are shown in Fig. 6A. A
comparison of percent photobleaching between contracting hearts and noncontracting hearts (13.6 ±  0.43% vs
12.8 ± 0.36%) (Fig. 6B) did not reveal significant differences (p = 0.231). The initial slope of recovery was greater
in hearts before inhibition (Fig. 6C) and tau was shorter (Fig. 6D), demonstrating significantly increased NADH
and ATP production rates when contraction is not inhibited.
Dehydrogenase activity and ischemia/reperfusion. Acute ischemia/reperfusion injury was studied
using NADH ED-FRAP to determine if the rate of NADH production was impaired after reperfusion. Typical
fNADH recovery curves before and after ischemia/reperfusion injury are shown in Fig. 6E. The initial rate of
recovery was almost twice as fast before ischemia than after reperfusion (8.6 ± 2.0 vs 4.4 ± 1.2 A.U./100 msec,
respectively) (p = 0.04) (Fig. 6G). The fNADH recovery time constant tau was also significantly longer (p =  0.049)
after reperfusion than before ischemia (5.7 ± 0.8 vs 4.1 ± 0.6 sec, respectively) (Fig. 6H). Percent photobleaching
was not significantly different (p = 0.419) before ischemia and after reperfusion (Fig. 6F).

Discussion

We have shown that the recovery kinetics of fNADH after photobleaching reproducibly represent changes in
NADH production during a variety of physiologic perturbations and provides insight into myocardial energy
production beyond that of only monitoring changes in unbleached fNADH. In particular, unbleached fNADH
represents the combination of NADH production and utilization but NADH ED-FRAP assesses the rate of
NADH production, with the important assumption that NADH utilization does not change during the assessment. Indeed, a primary advantage of NADH ED-FRAP is that NADH production can be assessed without
altering the physiological conditions of the tissue. We also identified optimal nondestructive NADH ED-FRAP
parameters: 23.8 mJ of photobleaching light energy delivered with a pulse width of 6 msec and a duty cycle of 50%.
These parameters provide reproducible assessments of dehydrogenase enzyme activity within epicardial tissue.
Our studies also reveal that multiple applications of high total light energies should be avoided to prevent tissue
photodamage.
NADH ED-FRAP parameters were optimized in studies that analyzed a range of delivered energies (TEDs)
and four modes of NADH photobleaching. As presented in Fig. 2, percent photobleaching and the initial slope of
fNADH recovery were dependent upon TED values below 18.2 mJ. Percent photobleaching and initial slope were
not significantly different for TED values above 18.2 mJ. Similar results were reported by Combs and Balaban
Scientific Reports | 7:45744 | DOI: 10.1038/srep45744
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Figure 6. NADH ED-FRAP measurements (LP mode) showing the effect of contraction (top row) and
ischemia/reperfusion (bottom row) on the rate of NADH production in perfused hearts. (A) Representative
fNADH data were fitted (‘y’ in Equation 4) and plotted for NADH ED-FRAP applied to contracting hearts
and non-contracting hearts electromechanically uncoupling with BDM. (B) Percent photobleaching was not
significantly different between contracting and non-contracting hearts (p >  0.05, n =  6). (C) The initial slope
of fNADH recovery was significantly higher in contracting hearts (p =  0.015, n =  6). (D) The time constant
of fNADH recovery (tau) was significantly shorter in contracting hearts (p <  0.001, n =  6). (E) Representative
fNADH data were fitted (‘y’ in Equation 4) and plotted for NADH ED-FRAP applied before ischemia and
10 min after reperfusion. Hearts were electromechanically uncoupled with BDM. (F) Percent photobleaching
was not significantly different before ischemia and after reperfusion (p >  0.05, n =  5). (G) The initial slope of
fNADH recovery was significantly lower after reperfusion (p =  0.04, n =  5). (H) The time constant of fNADH
recovery (tau) was significantly longer after reperfusion (p =  0.049, n =  5).

in isolated cardiac myocytes2. In those studies, the recovery rate of fNADH increased when the level of NADH
photolysis increased by either changing the overall power of the laser or the number photobleaching pulses.
These results emphasize that, for any set of experiments, a standard mode of photobleaching should be used
for all measurements to reduce measurement variability. Our results also indicate that percent recovery and tau
are likely not as sensitive to TED (Fig. 2C,D). While percent recovery was close to 100%, it is possible that the
photobleaching of background, non-NADH fluorophores (~15% of NADH fluorescence) may have occurred.
Similarly, any loss of the total NAD+: NADH pool could have prevented full fNADH recovery3. Although tau
was dependent upon the photobleaching mode, the effect of TED on tau within each photobleaching mode was
not significant (Fig. 2D). This suggests that tau could be a more robust indicator of dehydrogenase activity when
systematic delivery of a specific TED cannot be guaranteed.
We observed that low power UV illumination (1.5 mW) used to image fNADH does not cause measurable
photobleaching of epicardial tissue (Fig. 3A). This could be the result of an increase in NADH production to
balance NADH photolysis or simply the result of negligible NADH photolysis by such low power light. We also
observed that UV illumination for NADH photobleaching (500 mW and a TED of 23.8 mJ) applied using the
long pulse (LP) mode is non-destructive and that several NADH ED-FRAP measurements can be obtained from
the same site without considerably altering subsequent measurements (Figs 3B and 4C). After analyzing percent
photobleaching, initial slope, tau, and percent recovery for all photobleaching modes, we chose the LP mode and
23.8 mJ for all subsequent experiments. With this mode, TED is situated within the percent photobleaching plateau (Fig. 2A) and the pulse width of 6 msec is compatible with most software and hardware for the development
of custom NADH ED-FRAP applications. Shorter pulse widths, such as 200 μsec for the SP mode, often require
specialized hardware and software.
Scientific Reports | 7:45744 | DOI: 10.1038/srep45744
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It is generally understood that enzyme activity is positively correlated with temperature, with dependencies
ranging from sub-freezing to high temperatures25–27. This correlation is the basis for therapeutic hypothermia in
patients suffering from cardiac arrest and the lowering of core temperature during cardiac surgeries that require
cardiopulmonary bypass28,29. When myocardial temperature is lowered, heart rate, contractile force, oxygen consumption, and, ultimately, ATP utilization all drop dramatically. A reduction in myocardial temperature decreases
both the steady state utilization and production rate of ATP, as well as decreases the upstream utilization and production of NADH. We therefore studied hearts perfused at three different temperatures (~22, ~30 and ~37 °C)
to test whether or not NADH ED-FRAP would detect a temperature-dependent slowing of NADH production.
Indeed, the recovery kinetics of fNADH dropped as temperature dropped, indicating a significant decrease in
NADH production rate (Fig. 5). Overall, the relationship between initial slope and temperature (Fig. 5A) and tau
and temperature (Fig. 5B) was proportional, although tau appeared to increase more between 30 & 22 °C than
between 37 & 30 °C, indicating that the relationship may have an exponential component. Additionally, GDH
activity was measured as an independent validation of the effect of temperature on a mitochondrial enzyme
actively involved in NADH production. The progressive drop in GDH activity as temperature was lowered, which
we measured using a standard molecular assay, indicates that fNADH recovery kinetics (initial slope and tau)
during NADH ED-FRAP mirrors changes (Fig. 5D) in the activity of a NADH producing enzyme found in the
mitochondria.
Total myocardial energy consumption is determined by actomyosin crossbridge cycling (~76%), calcium
transport (~15%), and the maintenance of sarcolemmal potential by the Na+/K+  ATPase (~9%)30,31. Thus, actomyosin ATPase inhibition via electromechanical uncoupling significantly diminishes myocardial energy consumption, which slows ATP production and slows upstream NADH production. We have previously shown that
fNADH rises rapidly in contracting hearts after the termination of flow to the aorta, reaching a plateau (full
reduction of NADH) within ~90 sec. In contrast, NADH accumulation during ischemia in electromechanically
uncoupled hearts is much slower and reaches a plateau after 5–10 min13,32. These differences in the rate of NADH
production were confirmed by the higher initial slopes and shorter values of tau that we measured via NADH
ED-FRAP (Fig. 6C,D). Although the motion of contraction introduced some oscillation in fluorescence acquired
during NADH ED-FRAP, the oscillation frequency was much higher than the slower average rise of fNADH,
providing for adequate analysis of recovery kinetics.
Our results indicate that NADH ED-FRAP is a useful approach for measuring NADH production after metabolic insults and provide additional insight into the sustained effects of ischemia/reperfusion injury in isolated
perfused hearts. Ischemia/reperfusion injury is a complex phenomenon that begins when mitochondrial oxygen availability is compromised during ischemia. Mitochondrial NADH subsequently rises13,33 and fatty acid
and carbohydrate oxidation are halted34. After reperfusion, cardiac energy production remains compromised,
likely due to an imbalance between glycolysis and full glucose oxidation34,35. Mitochondrial damage caused by
reperfusion is another important mechanism of impaired myocardial energetics, which is thought to be caused
by intracellular Ca2+ overload36, mitochondrial ROS production, and opening the mitochondrial permeability
transition pore37–39. Mitochondrial damage would likely motivate dysfunction of complex I, III and IV of the
electron transport chain (ETC), which has been shown to persist for at least 10–15 min after reperfusion. Such
dysfunction has been ascribed to a greater disintegration and loss of cardiolipin40–43, a key phospholipid located in
the mitochondrial membrane and is thought to serve as a proton trap within the ETC44,45. ROS-induced oxidative
damage during metabolic insults can also damage cardiolipin41,42, which may further contribute to mitochondrial
dysfunction after reperfusion.
Overall, our results are consistent with the known outcomes of reperfusion injury, where we observed a significant difference before and after reperfusion in both the initial slope of fNADH recovery (Fig. 6G) and the
recovery time constant tau (Fig. 6H). These data provide the interesting observation that, even after 10 min of
reperfusion, the rate of NADH production remained lower than the pre-ischemic level, likely the result of sustained mitochondrial damage. It is interesting that low levels of NADH production were maintained even though
heart rate returned to the pre-ischemic level: 196 ± 12 bpm before ischemia and 183 ± 12 bpm after ischemia
(p = 0.096). It is unlikely that the imposed 20 min of global ischemia confounded (other than the injury itself)
the NADH ED-FRAP signal observed after 10 min of reperfusion given the rapid oxidation of NADH and restoration of fNADH to a level similar to that before ischemia, analogous to previous studies of ischemia in isolated
hearts46–48.

Conclusions

Ultraviolet energy delivered between 21–23.8 mJ provided consistent NADH photobleaching within epicardial
tissue for the assessment of NADH production rate during multiple metabolic perturbations. As perfusate temperature was reduced the kinetics of fNADH recovery after photobleaching directly correlated with glutamate
dehydrogenase activity, with longer recovery of fNADH corresponding to lower glutamate dehydrogenase activity. fNADH recovery kinetics after photobleaching remained significantly impaired after 10 min of reperfusion
after global ischemia, indicating sustained impact of ischemia/reperfusion on dehydrogenase activity. High rates
of NADH production were associated with physiologic temperature and the greater energetic demands of contraction. Overall, our results indicate that myocardial NADH ED-FRAP is a useful non-destructive approach for
assessing dehydrogenase activity within living myocardium.

Limitations

Potential limitations include the risk of ischemic damage during the heart excision and cannulation, thus the time
from excision to cannulation was minimized. Most excised heart preparations are prone to oxygen limitations, in
part because the perfusate does not contain red blood cells31. However, red blood cells are typically not added to
perfusate because of the dominating optical absorption of haemoglobin (250–650 nm range). Another potential
Scientific Reports | 7:45744 | DOI: 10.1038/srep45744

9

www.nature.com/scientificreports/
limitation is that fNADH was imaged from a thin layer of epicardial tissue and may not reflect transmural gradients of dehydrogenase activity, which is a relevant concern. This could be especially important during the first
moments of ischemia because ischemia begins within endocardial tissue and progresses as an anoxic wave to the
epicardium49. The rate and spatial extent of the progression of this wave is variable and modulated by factors such
as wall stress and myocardial perfusion50–52. However, in our studies NADH recovery kinetics were measured
after 10 min of reperfusion, an interval after which transmural gradients were likely to have stabilized. Finally, our
fNADH measurements do not discriminate between NADH fluorescence and NADPH fluorescence. Nonetheless,
the contribution of NADPH fluorescence in such measurements is thought to be insignificant due to its much
lower concentration compared to NADH53,54 and minimal fluorescence enhancement within the mitochondria55.

Materials and Methods

Perfused heart preparations.

Animal protocols were approved by The George Washington University’s
Animal Care and Use Committee. All experiments were performed in accordance with the Guide for the Care
and Use of Laboratory Animals published by the National Institutes of Health. Sprague-Dawley rats (315 ± 8.8 g,
either sex) were anesthetized via an intraperitoneal injection of Telazol (40 mg/kg). Upon the cessation of pain
reflexes, hearts were quickly excised, cannulated via the aorta, and Langendorff perfused at constant pressure
(70 mmHg) and temperature (37 °C, except as noted) with an oxygenated (95% O2, 5% CO2) Krebs-Henseleit
solution, containing, in mM: 118 NaCl, 4.7 KCl, 1.25 CaCl2, 0.57 MgSO4, 1.17 KH2PO4, 25 NaHCO3, 6 glucose
and 500 mU/L insulin, pH = 7.4. Exogenous fatty acids were not added to the perfusate mainly because in isolated heart preparations the availability of endogenous fat is sufficient to properly maintain cardiac mechanical
function for at least 60 min56, which provided for the completion of our NADH ED-FRAP protocols. For most
experiments, the actomyosin ATPase inhibitor 2,3-butanedione monoxime (BDM, 15 mM) was administered
to electromechanically uncouple the hearts to minimize motion artifacts during fluorescence imaging57,58. An
electrocardiogram (ECG) was continuously acquired using a bioamplifier (Dagan EX4-400) and a PowerLab data
acquisition system (AD Instruments).

NADH ED-FRAP illumination and imaging.

Two UV LED spotlights (PLS-0365-030-S & LCS-036511-22, Mightex Systems) provided light (367 ± 5.5 nm) to illuminate the epicardium. A low power spotlight
(1.5 mW) was used for continuous NADH fluorescence (fNADH) imaging and a high power spotlight (500 mW)
was used to photobleach epicardial NADH. The high power spotlight illuminated epicardial regions of approximately 7 mm2 (Fig. 1A). Prior to each experiment, a single image was acquired with the high power spotlight at
low power (0.71 mW) to locate epicardial regions for subsequent fNADH recovery analysis. Emitted epicardial
fluorescence was band-pass filtered (475 ± 25 nm, peak 460 nm18) and imaged at 10 Hz using a CCD camera
(Andor iXon DV860). A background image (no lights) and a reference image (low power light source on, but
no heart) were acquired before beginning each study. These images were stored and used for off-line analysis
to automatically remove the baseline counts for each pixel. The lights and camera were synchronized using a
custom LabVIEW (National Instruments) program. A typical NADH ED-FRAP protocol was: 5 sec of baseline
(control) imaging, a brief period of NADH photobleaching (0.30–8.0 sec, described below), and 95 sec of continuous imaging to record fluorescence recovery (Fig. 1B). Percent photobleaching was calculated with respect to
the average fNADH level during the 5 sec of baseline imaging before photobleaching. One-dimensional spatial
fNADH profiles were computed by interpolating fNADH along a user-defined 3.3mm line (one pixel wide) that
passed through a photobleached area (Fig. 1C).

Full range of fNADH: fully oxidized to fully reduced. The range of fluorescence from fully oxidized to
fully reduced NADH was measured to determine the percentage of the total NADH pool that was photobleached.
Baseline fNADH was imaged and then perfusate flow to the aorta was terminated, causing global ischemia and
full reduction of the mitochondrial NADH pool (Fig. 1B). fNADH was acquired until fluorescence plateaued
(97 ± 8 sec after initiating global ischemia). In other hearts, after imaging baseline (control) fNADH, carbonyl
cyanide m-chlorophenylhydrazone (CCCP, 10 μM) was added to the perfusate to dissipate the mitochondrial
proton gradient, fully oxidizing NADH, causing the fNADH signal to drop59. The NADH pool was considered
to be fully oxidized when both the fNADH signal plateaued to a minimum (204 ± 8 sec after fNADH began to
fall) and illumination with the high power UV LED did not cause an additional drop in fNADH. After acquiring
the fNADH maxima and minima from multiple studies the data were normalized using the following equation:
nfNADH (t ) =

fNADH (t ) − fNADH min
fNADH max − fNADH min

(1)

where fNADH(t) is the fNADH signal acquired during a study, fNADHmax is the maximum fluorescence intensity when NADH is fully reduced and fNADHmin is the minimum fluorescence intensity when NADH is fully
oxidized.

Optimization of NADH ED-FRAP parameters.

Multiple variables were studied to determine optimal
photobleaching parameters. The total energy delivered (TED) for photobleaching was optimized by increasing
TED from 2.8 to 28 mJ while analyzing 4 key parameters (Fig. 1D): (1) Percent photobleaching, the drop in
fNADH that occurs immediately following illumination with high-intensity UV light; (2) Tau, the time constant
of the rise (τ) of fNADH after photobleaching; (3) Initial slope, the recovery rate of fNADH during the first second after photobleaching; and (4) Percent recovery, the degree to which fNADH recovered to baseline.
Approaches for delivering optimal TED for photobleaching were defined to study how TED might best be
applied. As such, four photobleaching modes were defined with specific light power, duty cycle, and pulse widths
(Table 1), with each providing equal TED. For example, while maintaining TED at 23.8 mJ, the effect of decreasing
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Energy Per Pulse

Total Bleaching Time

# of Pulses

Total Energy Delivered

Long Pulse (LP)

Light Power
500 mW

Duty Cycle Pulse Width
50%

6 msec

28 μJ

5.1 sec

850

23.8 mJ

Short Pulse (SP)

500 mW

50%

200 μsec

0.934 μJ

5.1 sec

25482

23.8 mJ

Low Light Power (LLP)

375 mW

50%

6 msec

21 μJ

6.8 sec

1132

23.8 mJ

Single Pulse (1P)

500 mW

100%

1 pulse

Continuous

2.55 sec

1

23.8 mJ

Table 1. Parameters for the four photobleaching modes used during the photobleaching optimization
studies (Fig. 2). Results indicated that the LP mode was the optimal photobleaching mode for NADH EDFRAP.

the length of each individual light pulse was tested by decreasing the pulse width from 6 msec (Long Pulse, LP)
to 200 μsec (Short Pulse, SP), while light power (500 mW), duty cycle (50%), and total bleaching time (5.1 sec)
remained constant between the two conditions (Table 1). Next, 375 mW (Low Light Power, LLP) was used to
measure the effect of reducing the light power by 25%. Duty cycle remained at 50% with a pulse width of 6 msec.
This increased total photobleaching time to 6.8 sec while maintaining TED at 23.8 mJ (Table 1). Finally, the
effect of a single pulse (1P) for photobleaching was tested, which dropped total bleaching time to 2.55 sec while
maintaining a TED of 23.8 mJ. Each photobleaching mode (LP, SP, LLP, and 1 P) was tested at each TED (2.8 to
28 mJ). The number of pulses, duty cycle, and pulse width for each photobleaching mode was controlled using
our LabVIEW program, which also synchronized with the camera and ensured that the camera did not acquire
images during photobleaching to prevent damage to the CCD.

Measurement of tissue viability and cellular damage. The effect of UV illumination on tissue viability
and cellular morphology was assessed using triphenyltetrazolium chloride (TTC) tissue staining and haematoxylin and eosin (H&E) histology. Epicardial sites where NADH ED-FRAP was applied using one of the four modes
of photobleaching (Table 1) were marked with permanent blue ink. As a positive control, several hearts were also
subjected to 10 min of continuous UV illumination at the maximum LED power (500 mW). Heart perfusion was
maintained for at least two hours after completing the UV illumination protocols to provide time for the rundown of cellular metabolism and any cellular necrosis to occur that might have resulted from UV photodamage.
Hearts were then incubated in a TTC solution (42 mM) at 37 °C for 10 min to reveal non-viable tissue. TTC stains
metabolically active tissue a deep red color, with metabolically inactive or damaged tissue presenting as a pale
tan color60. Tissue damage was assessed in this way for three hearts subjected to each photobleaching mode. A
subset of hearts was fixed in 10% formalin and cross-section slices were prepared for H&E staining to examine
cell morphology. Haematoxylin stains the nuclei of cells as blue/purple and eosin stains nonspecifically stains
proteins as pink61.
Dehydrogenase activity and temperature.

Low temperatures slow the rate of enzyme-catalyzed reactions so we tested whether NADH ED-FRAP would reveal the effect of a drop in perfusate temperature on the
rate of NADH production in perfused hearts. These experiments were performed using the LP mode of photobleaching with a TED of 23.8 mJ (Table 1). Perfusate temperature was set at either 22 ± 0.18, or 30 ±  0.16, or
36.6 ± 0.11 °C for each study. The rate of fNADH recovery was measured after multiple rounds of photobleaching
at each perfusate temperature.
Glutamate dehydrogenase (GDH) activity was determined using enriched mitochondrial fractions to correlate
the rate of fNADH recovery measured after photobleaching with the activity of an NADH producing enzyme that
resides within the mitochondria. Enriched mitochondrial fractions were extracted from ventricular tissue and
0.08–0.13 μg of protein was added to a cuvette containing, in mM: 50 TEA, 2.5 EDTA, 100 ammonium acetate, 1
ADP, 0.2 NADH, and 2 kU/L lactate dehydrogenase, in a final volume of 1 mL, pH = 7.6. Background absorbance
was measured at 340 nm for 1 min in a spectrophotometer (SpectraMax Plus 384, Molecular Devices). The addition of 2-oxogluterate (7 mM) initiated substrate-dependent activity and A340 was measured at 340 nm for 2 min.
GDH activity was calculated using an NADH millimolar extinction coefficient of 6.23. Average temperatures for
GDH activity measurements were 22 ±  0.01, 30 ± 0.01, and 37 ± 0.01 °C.

Dehydrogenase activity and contraction.

The actomyosin ATPase is a major consumer of myocyte
ATP and its rate of ATP hydrolysis modulates the rate of mitochondrial NADH production. In a separate set of
studies the impact of actomyosin ATPase activity on fNADH recovery after photobleaching was measured. Before
administering the actomyosin ATPase inhibitor BDM, NADH ED-FRAP was applied to contracting perfused
hearts. BDM was then administered and hearts were monitored until the cessation of contractions and a stable
heart rate were observed. NADH ED-FRAP was performed again to compare fNADH recovery kinetics before
and after actomyosin ATPase inhibition.

Dehydrogenase activity and ischemia/reperfusion.

Acute ischemia/reperfusion injury has been
reported to diminish mitochondrial ATP production62,63. If so, then the rate of NADH production may also
be lower after ischemia/reperfusion injury. We tested this hypothesis in a separate set of perfused heart studies
using NADH ED-FRAP. Baseline fNADH recovery kinetics were measured before aortic flow was halted for
20 min. Hearts were reperfused for 10 min, after which fNADH recovery kinetics were measured again via NADH
ED-FRAP. fNADH recovery kinetics measured before and after global ischemia/reperfusion were then compared.
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Data analysis.

NADH fluorescence images were recorded using Solis imaging software (Andor) and
extracted using ImageJ. To compute an fNADH signal, a region of interest (ROI) within the photobleached region
was selected and all pixels within that ROI were averaged to provide a temporal fNADH signal: fNADH(t). Percent
photobleaching and percent recovery with respect to baseline were calculated using the following equations:
% photobleaching =

% recovery =

fNADH _photobleach ∗ 100
fNADH _baseline

fNADH _recovery ∗ 100
fNADH _baseline

(2)

(3)

where fNADH_photobleach is the minimum fluorescence intensity after high power UV light was applied to the
epicardial surface, fNADH_recovery is the fluorescence intensity when the recovery reached a steady-state, and
fNADH_baseline is the average fluorescence intensity during the first 5 sec before photobleaching.
The time constant of fNADH recovery after photobleaching (tau) was computed using a least-squares fit of
the following equation to the fluorescence ROI data (fNADH(t)) acquired during the fNADH recovery phase
(Fig. 1B):
y = A − B ∗ e−T/τ

(4)

where A is the baseline value from which the signal is rising, B is the signal amplitude, T is time (sec), and tau (τ,
1/sec) is the inverse of the exponential rate constant of rise, or the time constant, when the amplitude reaches 63%
of recovery. The initial slope of the fNADH recovery curve was also calculated by computing the first derivative
of the fitted recovery line (y, Equation 4) averaged over the first second of recovery. Data were analyzed using
custom Matlab scripts and plotted using Spyder (Python 2.7).

Statistical analysis. Statistical analyses were performed using Minitab 16 and Microsoft Excel. Data are
presented as mean ± standard error of the mean. A paired t-test or an analysis of variance (ANOVA) general
linear model (GLM) with Tukey post-hoc test, as appropriate, was used to compare between different groups.
Significance was defined as p < 0.05. An Anderson–Darling test was performed to determine normality in the
data.
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